AstraZeneca Pharma India Gets Approval to Import Fasenra for EGPA

The regulatory nod from the Central Drugs Standard Control Organisation (CDSCO) allows for the import and distribution of Benralizumab (Fasenra) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

AstraZeneca Pharma India Limited has secured permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import and sell Benralizumab 30 mg/mL solution for injection—marketed as Fasenra—for an additional indication. This development expands the clinical utility of the biologic in India, providing a new treatment avenue for patients suffering from relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

The authorization marks a significant expansion in the therapeutic scope for Fasenra, which was previously approved in India as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. By broadening the indication to include EGPA, a rare and complex inflammatory condition, AstraZeneca continues to strengthen its respiratory and immunology portfolio within the Indian market.

Expanding Access to Advanced Biologic Therapy

The approval for the additional indication of EGPA allows healthcare professionals to offer a targeted treatment option for a condition that has historically been difficult to manage. EGPA is characterized by inflammation of the blood vessels, often accompanied by asthma and high levels of eosinophils, a type of white blood cell.

Fasenra operates by binding to the IL-5 receptor alpha on eosinophils, effectively reducing the levels of these cells in the blood and tissues. The inclusion of EGPA in the permitted list of indications underscores the growing role of monoclonal antibodies in treating systemic inflammatory diseases in India. The import permission is subject to the receipt of all relevant statutory licenses and regulatory requirements.

Impact on Patients and Healthcare

The availability of Fasenra for EGPA patients is expected to address a critical unmet need for effective, long-term management strategies. Patients with relapsing or refractory forms of the disease often face significant health challenges, and the introduction of this biologic therapy provides a specialized tool for physicians to manage chronic inflammation and improve patient quality of life.

For the healthcare sector, this approval reinforces the importance of biologic drugs in the treatment of rare and autoimmune-related conditions. AstraZeneca Pharma India, which has maintained a significant presence in the country for over four decades, continues to focus on introducing its global innovation pipeline to the Indian patient population.

Official Sources

According to official regulatory filings submitted to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), the company received the import and market permission in the form of a formal regulatory nod from the CDSCO. The company stated that the permission facilitates the sale and distribution of Benralizumab for the newly approved indication.

Why It Matters

This regulatory milestone is crucial for patients struggling with the debilitating effects of EGPA. By providing a targeted biologic therapy, the medical community gains a more effective means of controlling inflammation and reducing the reliance on oral corticosteroids, which often carry significant long-term side effects. It represents a strategic step in AstraZeneca’s mission to provide life-changing medicines to Indian patients.

Key Facts at a Glance

• Drug Name: Benralizumab (Fasenra) 30 mg/mL solution for injection.

• Regulatory Approval: Granted by the Central Drugs Standard Control Organisation (CDSCO).

• New Indication: Add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

• Previous Indication: Already approved for the add-on maintenance treatment of severe eosinophilic asthma in adults.

• Administration: Administered via subcutaneous injection.

FAQ: Understanding the Development

What is Fasenra primarily used for? Fasenra is a monoclonal antibody primarily used as an add-on maintenance treatment for severe eosinophilic asthma. It has now also been approved for treating relapsing or refractory EGPA in adults.

How does Benralizumab work? It is an IL-5 receptor alpha-directed antibody that binds to eosinophils, helping to deplete them and reduce inflammation in the body.

Does this mean the drug is a cure for EGPA? No, Fasenra is not a cure. It is a maintenance treatment designed to help manage the disease and reduce the frequency of relapses or flare-ups.

Who should patients consult regarding this treatment? Patients should consult their pulmonologist, rheumatologist, or primary healthcare provider to discuss whether this treatment is suitable for their specific clinical condition.

Source: AstraZeneca Pharma India Limited Investor Relations, Central Drugs Standard Control Organisation (CDSCO), Bombay Stock Exchange (BSE)